Story
Oxford Biomedica Slashes 2026 Revenue Forecast by 17% on Client Delays

Oxford Biomedica has significantly lowered its fiscal 2026 revenue and profitability guidance, citing widespread delays in client orders and a slower-than-expected integration of a key U.S. facility. The U.K.-based gene and cell therapy company announced a roughly 17% reduction to its revenue forecast, signaling headwinds from shifting customer strategies.
Revised Financial Outlook
The company adjusted its forward-looking financial targets, which now stand substantially below previous expectations and current market consensus. The revised guidance points to a notable slowdown in anticipated growth.
- 2026 Revenue: The new forecast is for £180-200 million, a sharp decrease from the prior range of £220-240 million.
- 2026 Adjusted EBITDA Margin: The outlook was lowered to mid-single digits from a previous target of approximately 10%.
According to the company, the revised revenue midpoint is approximately 17% below current consensus estimates of £228 million. The new margin guidance, assuming a 5% margin, implies a potential 57% reduction from what analysts had been expecting.
Client Behavior and Operational Delays
AdOxford Biomedica attributed the guidance cut to several factors, primarily related to client ordering patterns. The company reported program deferrals and timeline delays stemming from clients' strategic decisions and clinical data outcomes. A change in procurement strategy at a larger client has also postponed order placement.
Furthermore, the company noted that several customers have adopted a staged approach to ordering work packages, which extends the time it takes to recognize the full value of signed contracts. Operationally, the integration of its Durham, North Carolina facility has progressed about six months more slowly than anticipated, though the site has now completed its first GMP run and is reportedly back on track.
Forward Guidance and H1 Performance
Despite the near-term challenges, Oxford Biomedica maintained its fiscal 2027 revenue growth guidance of 25-30%. However, it adjusted the corresponding 2027 adjusted EBITDA margin target to double-digit percentages, down from a previous goal of exceeding 20%, citing reduced revenue absorption.
In a preliminary update, the company reported that first-half 2026 revenues grew approximately 9% year-over-year to around £80 million. It also noted strong commercial momentum, having signed 17 new clients in the period, which is 30% more than in all of fiscal 2025. The company will report its full first-half results on September 22.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.